Thorne Healthtech Stock Fair Value Calculation – THORNE HEALTHTECH Reports Second Quarter Financial Results for FY2023
August 13, 2023
🌥️Earnings Overview
THORNE HEALTHTECH ($NASDAQ:THRN) announced their financial results for the second quarter of FY2023 (ending June 30 2023) indicating total revenue of USD 72.7 million, a year-on-year rise of 29.7%, and net income of USD 4.4 million, a growth of 179.6% compared to the previous year.
Stock Price
The company’s stock opened at 6.0 dollars and closed at 5.8 dollars, down 3.5% from its last closing price of 6.0 dollars. This marks a challenging quarter for THORNE HEALTHTECH, as the stock has seen a steady decline in the past months. Despite these setbacks, THORNE HEALTHTECH remains committed to developing innovative solutions to improve healthcare access and outcomes. They are continuing their efforts to launch new products to the market and to expand current services in order to increase revenue.
The company has also taken steps to reduce costs and improve operations, such as reorganizing its sales and marketing teams and streamlining its production processes. THORNE HEALTHTECH remains optimistic that these actions will help them turn their fortunes around in the upcoming quarters. They are confident that their innovative offerings and new strategies will help them compete in an increasingly competitive market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Thorne Healthtech. More…
| Total Revenues | Net Income | Net Margin |
| 255.95 | 20.33 | 7.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Thorne Healthtech. More…
| Operations | Investing | Financing |
| 21.52 | -40.59 | 18.55 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Thorne Healthtech. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 282.53 | 127.27 | 2.86 |
Key Ratios Snapshot
Some of the financial key ratios for Thorne Healthtech are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 30.7% | – | 6.0% |
| FCF Margin | ROE | ROA |
| -5.9% | 6.4% | 3.4% |
Analysis – Thorne Healthtech Stock Fair Value Calculation
At GoodWhale, we have conducted an in-depth analysis of THORNE HEALTHTECH‘s fundamentals. Our proprietary Valuation Line indicates that the fair value of THORNE HEALTHTECH share is around $6.2. Currently, the stock is traded at $5.8, representing a fair price which is 6.9% undervalued. This suggests that investors may be able to capitalize on this mispricing and reap potential returns from investing in THORNE HEALTHTECH currently. More…
Peers
The health technology industry is a highly competitive market. Thorne has a strong track record of innovation and success, which has allowed it to maintain its position as a top player in the health technology industry.
– Vitana-X Inc ($OTCPK:VITX)
Vitana-X Inc is a company that specializes in the development and sale of vitamins and supplements. The company has a market cap of 413.71k as of 2022 and a return on equity of 270.71%. Vitana-X Inc has been in business for over 20 years and is a well-established company in the industry. The company’s products are available in over 50 countries and are sold through a variety of channels, including online, retail, and wholesale. Vitana-X Inc is a publicly traded company on the OTCQB exchange under the ticker symbol VTXI.
– By-health Co Ltd ($SZSE:300146)
The company’s market cap is 30.57B as of 2022. The company’s ROE is 11.34%. The company is involved in the manufacture and sale of health products.
– Wellnex Life Ltd ($ASX:WNX)
Wellnex Life Ltd is a biotechnology company that focuses on the development and commercialization of products for the treatment of osteoporosis and other bone-related diseases. The company has a market cap of 25.9M as of 2022 and a Return on Equity of -62.84%. Wellnex Life Ltd is headquartered in Vancouver, Canada.
Summary
THORNE HEALTHTECH recently reported their financial results for the second quarter of FY2023, showing strong growth in revenue and net income. Total revenue reported was USD 72.7 million, a 29.7% increase year-over-year, and net income of USD 4.4 million, a 179.6% increase from the same period in the previous year. While the financial results are encouraging, the stock price moved down the same day, likely due to investor concerns in the current market. As such, it is important for investors to take a closer look at THORNE HEALTHTECH and assess their potential risk/reward before investing.
Related Posts
Recent Posts
